PHARMACY

Omnicare and McKesson expand sourcing and distribution agreement

BY Michael Johnsen

CINCINNATI — Omnicare and McKesson on Monday announced the signing of an expanded agreement to include the sourcing and distribution of branded, specialty and generic pharmaceuticals. The new five year agreement extends through December 2019.
 
For over ten years, Omnicare has partnered with McKesson for the distribution of branded pharmaceuticals. As part of the expanded agreement, McKesson will now also assume responsibility for the sourcing and distribution of generic pharmaceuticals for Omnicare as part of McKesson’s proprietary OneStop generics program.
 
“Following a thorough review of our strategic sourcing alternatives, we determined an expanded partnership with McKesson provided the best pathway for our company amid the rapidly evolving pharmaceutical supply chain,” said Nitin Sahney, Omnicare’s president and CEO. “By leveraging McKesson’s sourcing and distribution expertise across our significant scale, we are better positioned to optimize our core competency of providing high-quality complex patient care.”
 
“Omnicare has been a valued customer to McKesson for more than a decade, and I am very pleased with the expansion of our relationship,” said John Hammergren, chairman and CEO, McKesson Corp. “I am extremely proud of our proven global sourcing expertise, industry-leading service levels and strong operational excellence, and I appreciate the opportunity to deliver additional value for Omnicare through this expanded relationship.”
 
Omnicare noted that it believes the benefits of its new sourcing strategy will be a key driver in enabling it to generate a low double-digit adjusted cash EPS growth rate in 2015.
 
“We have made steady progress executing our multi-layered growth strategy, and are well positioned to continue generating favorable results for our shareholders,” concluded Sahney.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

PHARMACY

Dr. Reddy’s launches generic Taxotere

BY Ryan Chavis

HYDERABAD, India — Dr. Reddy's Labs on Monday announced the launch of docetaxel injection USP in 20-mg and 80-mg dosage strengths. The drug is the generic version of Taxotere.
 
Taxotere brand and generic had sales in the United States of $218 million for the 12 months ending September 2014, according to IMS Health data. The drug is used to treat various types of cancer
 
Dr. Reddy's docetaxel injection USP are available as a single dose, one-vial formula that doesn't require a prior dilution and is ready to add to the intravenous infusion solution, the company stated. 

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

PHARMACY

PQA endorses new performance measure

BY Michael Johnsen

SPRINGFIELD, Va. — The membership of the Pharmacy Quality Alliance has endorsed a new performance measure, Statin Use in Persons with Diabetes, the group announced Friday. 
 
This measure evaluates the percentage of patients ages 40 years to 75 years who were dispensed a medication for diabetes and who also receive a statin medication. It is based on the 2013 American College of Cardiology/American Heart Association Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults. PQA member organizations had the opportunity to submit written comments regarding the newly developed and tested performance measure, participate in a phone conference hosted by PQA staff to discuss the measure and address questions, and, finally, to vote electronically on its endorsement. PQA reported that 90% of member respondents voted to endorse the Statin Use in Persons with Diabetes measure.
 
The National Quality Forum board of directors also announced on November 14 that it endorsed eight measures related to Patient Safety conditions, two of which are PQA measures. Overall, the eight NQF-endorsed Patient Safety measures focus on healthcare associated infections, including an ad hoc measure on sepsis, medication safety and general patient safety. NQF evaluated a total of 17 measures against their endorsement criteria; four new measures, 12 maintenance measures and one ad hoc measure were reviewed by the Consensus Standards Approval Committee.  Additional information and a complete list of the 17 measures can be viewed on the NQF project page

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES